Answers are grounded in this paper and cite their sources.
Adherence to pharmacological treatment in neuropsychiatric disorders represents a clinical and public health challenge, as nonadherence is associated with relapses, hospitalizations, and increased healthcare costs. In these conditions, cognitive, motivational, and psychosocial factors interfere with therapeutic follow-up, generating nonadherence rates that may range from 40% to 60%, particularly in diagnoses such as schizophrenia and bipolar disorder. The aim of this study is to analyze adherence levels (high, medium, and low) in a sample of adults with neuropsychiatric disorders and determine their association with sociodemographic variables, medical comorbidities, ICD-10 diagnosis, and pharmacological group. Observational study including 440 outpatients from the Instituto de Neurociencias de Guayaquil (2023–2024). Adherence was assessed using the MMAS-8 scale. Sociodemographic and clinical variables were described, and bivariate analyses using chi-square tests were conducted to explore associations. The sample had a mean age of 52.8 years (SD = 21.35); 53.6% were men. Diagnoses F20–F29 (32.7%) and F40–F48 (23.7%) predominated. Diabetes mellitus was reported by 72.7% of participants and arterial hypertension by 66.8%. Low adherence was predominant (71.6%), followed by medium (27.0%) and high adherence (1.4%). No significant differences were found according to sex, diabetes, or hypertension. Significant differences were observed by diagnostic group ( p < 0.001), with higher concentrations of low adherence in F20–F29 and F40–F48. No significant association was found with pharmacological group ( p = 0.380). Age showed minimal differences across adherence levels. Low adherence was highly prevalent in this cohort, particularly in psychotic and related disorders. The absence of association with sociodemographic and pharmacological variables suggests that adherence is a complex phenomenon more closely linked to clinical diagnosis and contextual factors. Personalized strategies and patient-centered care models are required to improve therapeutic outcomes in neuropsychiatric disorders.
No takes yet. Share an insight, caveat, or question.
Figueira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: